Clinical Trials
21 trialsNCT03842696 2026-01-27
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT03259503 2025-11-10
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03150329 2025-09-03
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01193842 2023-11-21
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00992446 2020-03-18
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT02589145 2019-12-13
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01789255 2018-07-24
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
Phase 2 Completed
NCT00837174 2017-09-19
COMBOSTAT
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT00601718 2017-05-25
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
Phase 1/2 Completed
NCT01120834 2017-04-10
Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
Weill Medical College of Cornell University
Phase 1/2 Completed
NCT00097929 2017-04-07
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00561418 2015-07-16
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00275080 2014-08-27
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00217412 2014-06-17
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00791011 2014-03-05
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Amgen
Phase 1 Completed
NCT00499811 2014-02-24
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00994500 2013-07-02
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005634 2013-06-19
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00045006 2013-05-30
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01116154 2010-12-09
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Terminated